Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection

• Published in: Cancer research (Chicago, Ill.) Ill.), 2009-03, Vol.69 (6), p.2358-2364
• Main Authors: POLSON, Andrew G, CALEMINE-FENAUX, Jill, FRANTZ, Gretchen, FUJI, Reina N, GRAY, Alane, HARDEN, Kristin, INGLE, Gladys S, KLJAVIN, Noelyn M, KOEPPEN, Hartmut, NELSON, Christopher, PRABHU, Saileta, RAAB, Helga, CHAN, Pamela, ROSS, Sarajane, STEPHAN, Jean-Philippe, SCALES, Suzie J, SPENCER, Susan D, VANDLEN, Richard, WRANIK, Bernd, YU, Shang-Fan, BING ZHENG, EBENS, Allen, CHANG, Wesley, CHRISTENSEN, Erin, CLARK, Suzanna, DE SAUVAGE, Frederic J, EATON, Dan, ELKINS, Kristi, ELLIOTT, J. Michael
• Format: Article
• Language: English
• Subjects: Animals; Antigens, CD - biosynthesis; Antigens, CD - immunology; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - pharmacokinetics; B-Lymphocytes - immunology; Biological and medical sciences; Cross-Linking Reagents - administration & dosage; Cross-Linking Reagents - pharmacokinetics; Female; Hematologic and hematopoietic diseases; Immunotoxins - immunology; Immunotoxins - pharmacokinetics; Immunotoxins - pharmacology; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Lymphoma, Non-Hodgkin - drug therapy; Lymphoma, Non-Hodgkin - immunology; Maytansine - administration & dosage; Maytansine - analogs & derivatives; Maytansine - pharmacokinetics; Medical sciences; Mice; Mice, Inbred ICR; Mice, SCID; Miscellaneous; Oligopeptides - administration & dosage; Oligopeptides - pharmacokinetics; Pharmacology. Drug treatments; Rats; Sulfhydryl Compounds - administration & dosage; Sulfhydryl Compounds - pharmacokinetics; Xenograft Model Antitumor Assays
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/0008-5472.can-08-2250

Antibody-drug conjugates (ADC), potent cytotoxic drugs covalently linked to antibodies via chemical linkers, provide a means to increase the effectiveness of chemotherapy by targeting the drug to neoplastic cells while reducing side effects. Here, we systematically examine the potential targets and linker-drug combinations that could provide an optimal ADC for the treatment for non-Hodgkin's lymphoma. We identified seven antigens (CD19, CD20, CD21, CD22, CD72, CD79b, and CD180) for potential treatment of non-Hodgkin's lymphoma with ADCs. ADCs with cleavable linkers mediated in vivo efficacy via all these targets; ADCs with uncleavable linkers were only effective when targeted to CD22 and CD79b. In target-independent safety studies in rats, the uncleavable linker ADCs showed reduced toxicity, presumably due to the reduced release of free drug or other toxic metabolites into the circulation. Thus, our data suggest that ADCs with cleavable linkers work on a broad range of targets, and for specific targets, ADCs with uncleavable linkers provide a promising opportunity to improve the therapeutic window for ADCs in humans.